What to Expect From Charles River Laboratories’ Next Quarterly Earnings Report

Core Insights - Charles River Laboratories International, Inc. (CRL) is valued at a market cap of $10.8 billion and operates as a global contract research organization (CRO) supporting drug discovery and development for various clients [1] Financial Performance - CRL is expected to announce its fiscal Q4 earnings for 2025 soon, with analysts predicting a profit of $2.33 per share, which represents a 12.4% decrease from $2.66 per share in the same quarter last year [2] - For fiscal 2025, analysts forecast CRL to report a profit of $10.22 per share, down 1% from $10.32 per share in fiscal 2024, but expect a rebound with a growth of 4.9% year over year to $10.72 in fiscal 2026 [3] Stock Performance - Over the past 52 weeks, CRL's stock has increased by 32.5%, outperforming the S&P 500 Index's 16.9% increase and the Health Care Select Sector SPDR Fund's 10.4% rise [4] - On December 22, shares of CRL rose about 3% following an upgrade to "Buy" by BofA Securities and the closure of an SEC investigation into the company's primate sourcing practices without enforcement action, alleviating investor concerns [5] Analyst Ratings - Wall Street analysts maintain a moderately optimistic outlook on CRL's stock, with an overall "Moderate Buy" rating; among 16 analysts, 11 recommend "Strong Buy" and five suggest "Hold" [6] - The stock currently trades above the mean price target of $209.57, with a Street-high target of $260 indicating an upside potential of 18.3% from current market prices [6]